Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.61 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.59 |
| ▸ | IKZF1 | Q13422 | 4/20 | 0.57 |
| ▸ | GSPT1 | P15170 | 2/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25646992 | 1.00 | CRBN (0.61) | CRBNIKZF2IKZF1GSPT1DDB1 | |
| SCHEMBL25646975 | 0.96 | CRBN (0.61) | CRBNIKZF2IKZF1GSPT1DDB1 | |
| SCHEMBL25278380 | 0.89 | CRBN (0.60) | CRBNIKZF2IKZF1GSPT1DDB1 | |
| SCHEMBL30459793 | 0.86 | IKZF2 (0.65) | CRBNIKZF2IKZF1 | |
| SCHEMBL30459997 | 0.85 | IKZF2 (0.64) | CRBNIKZF2IKZF1GSPT1DDB1 | |
| SCHEMBL24817833 | 0.85 | IKZF2 (0.64) | CRBNIKZF2IKZF1GSPT1DDB1 | |
| SCHEMBL24819312 | 0.85 | IKZF2 (0.64) | CRBNIKZF2IKZF1GSPT1DDB1 | |
| SCHEMBL25229574 | 0.84 | IKZF2 (0.66) | CRBNIKZF2IKZF1 | |
| SCHEMBL30460081 | 0.84 | IKZF2 (0.63) | CRBNIKZF2IKZF1GSPT1DDB1 | |
| SCHEMBL25228981 | 0.84 | IKZF2 (0.68) | CRBNIKZF2IKZF1GSPT1DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | claimed |